Since Thanksgiving is right around the corner, the FFL crew explains which players they are thankful for this year, including a running back in Jacksonville.
Since Thanksgiving is right around the corner, the FFL crew explains which players they are thankful for this year, including a running back in Jacksonville.
Hamilton, who already has the 2020 title won, tested positive on Monday after experiencing "mild" symptoms.
Critics of the current system have long argued that the rich don't pay their fair share of Social Security taxes. There's an earnings cap established each year that determines what level of wages workers pay taxes on. Here's why that's unfair: Someone earning $142,800 in 2021 will pay the same amount of Social Security tax as someone earning $400,000.
It's not been an easy year for either stock, but the advent of a coronavirus vaccine will herald an improvement in commercial aerospace, and that should benefit Boeing (NYSE: BA) and Raytheon Technologies (NYSE: RTX). Unfortunately, it's extremely difficult to accurately predict the shape of the recovery in the commercial aerospace market, so investors need to consider a range of outcomes. The downside risk if there is a weak recovery.
LAS VEGAS, NV, Dec. 01, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire \-- ISW Holdings, Inc. (OTC: ISWH) (“ISW Holdings” or the “Company”), a global brand management holdings company, is pleased to announce that the Company is negotiating with noteholders toward the establishment of a new agreement that will form the foundation for its emerging anti-dilution policy designed to protect the value of its common stock and return more of that value to its shareholders. The current negotiation contemplates an agreement whereby noteholders will exchange their notes for preferred restricted shares, reducing debt on the balance sheet and protecting shareholders against dilution. While this arrangement is not yet currently in place, the Company is making active strides toward establishing it in principle as a template for future funding rounds going forward.In addition, to augment this step, the Company has already begun to cancel out restricted shares in a process that it believes will lead to more than 8 million shares (nearly 25% of the Company’s outstanding shares) being returned back to treasury.“We are moving toward the commercial launch of our Cryptocurrency segment, which was established this summer through our partnership with Bit5ive, LLC,” noted Alonzo Pierce, President and Chairman of ISW Holdings. “We also continue to see very strong tangible growth in our Home and Telehealth Healthcare segment, where we just posted strong top and bottom-line data for Q3 and where we are already on pace to post new record numbers to close out the year. As these efforts get off the ground, we want to take steps now to ensure that the value we are creating confers to our common shareholders. In short, we are determined to keep the share structure attractive to investors while bringing in solid and growing revenues.”About ISW HoldingsISW Holdings, Inc. (ISWH), based in Nevada, is a diversified portfolio company comprised of essential business lines that serve consumer product demands. Our expertise lies in strategic brand development, early growth facilitation, as well as brand identity through our proprietary procurement process. Together, with our partners, we seek to provide a structure that meets large scalability demands, as well as anticipated marketplace needs. We are able to meet these needs through a variety of strategic innovative processes. ISWH is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration, and distribution efficiency. The company has also partnered with a well-known software development and consulting company, Bengala Technologies LLC, which is developing significant enhancements in the supply chain management space; and the partnership has a vitally needed patent now pending.Forward Looking StatementsThis press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with OTC Markets (www.otcmarkets.com).For more information, visit www.iswholdings.comCompany Contact:Investor Relationsinfo@ISWHoldings.com
Veterinary Anesthesia Equipment Market Research Report by Product (Accessories, Complete Anesthesia Machines, Gas Delivery Management Systems, Vaporizers, and Ventilators), by Animal Type (Large and Small), by End-Use - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Veterinary Anesthesia Equipment Market Research Report by Product, by Animal Type, by End-Use - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993426/?utm_source=GNW The Global Veterinary Anesthesia Equipment Market is expected to grow from USD 912.67 Million in 2019 to USD 1,383.28 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.17%. Market Segmentation & Coverage: This research report categorizes the Veterinary Anesthesia Equipment to forecast the revenues and analyze the trends in each of the following sub-markets: Based on Product, the Veterinary Anesthesia Equipment Market studied across Accessories, Complete Anesthesia Machines, Gas Delivery Management Systems, Vaporizers, Ventilators, and Waste Gas Management Systems. Based on Animal Type , the Veterinary Anesthesia Equipment Market studied across Large and Small. Based on End-Use, the Veterinary Anesthesia Equipment Market studied across Emergency service centers, Hospitals & Clinics, and Veterinary homecare settings. Based on Geography, the Veterinary Anesthesia Equipment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Veterinary Anesthesia Equipment Market including A.M. Bickford, Inc., Burtons Medical Equipment Ltd, Dispomed ltd, DRE Veterinary, Everest Veterinary Technology, Hallowell Engineering & Manufacturing, Henry Schein, Inc., JD Medical, Kent Scientific Corporation, Medical Developments International Limited, Mediquip Pty Ltd, Miden Medical, Midmark Corporation, Mindray Medical International, Patterson Companies, Inc., Rothacher-Medical GmbH, RWD Life Science, Smiths Medical, Inc., Soar Medical Tech, Supera Anesthesia Innovations, Vetland Medical Sales & Services, LLC, and Zhong Ke Base Medical Technology. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Veterinary Anesthesia Equipment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market. The report provides insights on the following pointers: 1\. Market Penetration: Provides comprehensive information on the market offered by the key players 2\. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3\. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4\. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5\. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments The report answers questions such as: 1\. What is the market size and forecast of the Global Veterinary Anesthesia Equipment Market? 2\. What are the inhibiting factors and impact of COVID-19 shaping the Global Veterinary Anesthesia Equipment Market during the forecast period? 3\. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Veterinary Anesthesia Equipment Market? 4\. What is the competitive strategic window for opportunities in the Global Veterinary Anesthesia Equipment Market? 5\. What are the technology trends and regulatory frameworks in the Global Veterinary Anesthesia Equipment Market? 6\. What are the modes and strategic moves considered suitable for entering the Global Veterinary Anesthesia Equipment Market? Read the full report: https://www.reportlinker.com/p05993426/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
According to the [175+ Pages] research report, the global 3D Scanner Market was estimated at USD 2.4 billion in 2019 and is expected to reach USD 6.8 billion by 2026. The global 3D Scanner Market is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2020 to 2027.New York, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Facts and Factors have published a new research report titled “3D Scanner Market By Component (Hardware, Software, Services), By Type (Portable, Desktop Based, Fixed Mount, Robot Mount), By End-User (Automotive, Healthcare, Aerospace & Defense, Education, Manufacturing, Media & Entertainment, Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026”.According to the research study, the global 3D Scanner Market was estimated at USD 2.4 billion in 2019 and is expected to reach USD 6.8 billion by 2026. The global 3D Scanner Market is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2020 to 2027.The Global 3D Scanner Market Is Powered By Increasing Need to Capture Large Volumes of 3D Data for Modelling and Analysis.The 3D scanner is basically used for capturing the three-dimensional views or attributes of a particular object along with its basic information like texture and color. It has benefits like it saves the time required in a manufacturing process and thereby makes the quality of output much better. Using light, x-rays, or laser technology the dimensions of an object can also be captured using a 3D scanner which further creates a point cloud that helps to produce a 3D representation of the object which is scanned with the help of software. 3D scanners are widely used in the automotive, construction, aerospace and defense, healthcare sectors among others.Browse through 33 Tables & 78 Figures spread over 175+ Pages and in-depth TOC on “Global 3D Scanner Market Size, Share & Trends Analysis Report and Forecast [2020-2026]”.Request Free Sample Report of Global 3D Scanner Market @ https://www.fnfresearch.com/sample/3d-scanner-market (The free sample of this report is readily available on request).Our Free Sample Report Includes:• Report Introduction, Overview, and In-depth industry analysis• 190+ Pages Research Report• Provide Chapter-wise guidance on Request• Regional Analysis with Graphical Representation of Size, Share & Trends• Includes List of table & figures• Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis• Facts and Factors research methodology(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)3D object demand is increasing at a higher pace because of manufacturing which is a major part of various end-use sectors such as medical, automotive, healthcare and pharmaceutical and these require quality assurance apart from the high cost of infrastructure. Due to the technological revolution, various imaging applications are launched in the market, and to enhance more of these imaging applications 3D scanners play a major role in the entire value chain. Also, laser 3D scanners are very popular in the healthcare sector and are becoming popular in the media and entertainment sector in the coming future. Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/3d-scanner-market(You may enquire a report quote OR available discount offers to our sales team before purchase.)Top Market PlayersSome of the leading and top companies in the 3D scanner market Hexagon AB, 3D Digital Corporation, Faro Technologies, Riegl Laser Measurement Systems GmbH, Creaform Inc., Carl Zeiss Optotechnik GmbH, Nikon Metrology, Perceptron Inc., Trimble Navigation Ltd., Ametek, GOM GmbH, Maptek, Topcon Corporation, among others.To know an additional list of market players, request a sample report: https://www.fnfresearch.com/sample/3d-scanner-marketThe rise in manufacturing, as well as industrialization, is the major factor that is boosting the market for 3D scanners. Also, 3D scanners are widely used in the aerospace, automobile as well as construction sectors. Automobile sectors are focusing on introducing new vehicles quickly and thereby reducing their product development cycle. Further, a rise in the occurrence of reverse engineering in countries such as China will also propel the demand for 3D scanners in the forecast period. The Healthcare sector uses 3D scanners for surgeries, CT scans, and are also used by dentists. 3D scanners are majority used in developing regions such as North America for crime investigation purposes which creates a huge market for the manufacturers. Another major use of 3D scanner s is for the maintenance of digital records of historical or cultural artifacts which are majorly in India, China, or the Middle East part those are considered as civilization cradles and have good historical treasures. These factors will drive the growth of 3D scanners market share to a larger extent during the forecast period.The market for the 3D scanner is segmented on the basis of component, type, end-user, and region. On the basis of components, the market is bifurcated into hardware, software, and services. On the basis of type, the market is segmented into the portable, desktop based fixed mount, and robot mount. Further, on the basis of end-users the market is bifurcated into automotive, aerospace and defense, healthcare, education, manufacturing, media & entertainment, and others. Browse the full “3D Scanner Market By Component (Hardware, Software, Services), By Type (Portable, Desktop Based, Fixed Mount, Robot Mount), By End-User (Automotive, Healthcare, Aerospace & Defense, Education, Manufacturing, Media & Entertainment, Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026" report at https://www.fnfresearch.com/3d-scanner-marketThe report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the 3D scanner sector. Key strategic developments in 3D scanner market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the 3D scanner market are appropriately highlighted in the report.The global 3D scanner market size is experiencing significant growth that is expected to continue over the upcoming years. Also, the rise in manufacturing, as well as industrialization, is the major factor that is boosting the market for 3D scanners. Also, 3D scanners are widely used in the aerospace, automobile as well as construction sectors.The 3D scanner market research report delivers an acute valuation and taxonomy of the 3D scanner industry by practically splitting the market on the basis of different components, types, end-users, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026.Request Customized Copy of Report @ https://www.fnfresearch.com/customization/3d-scanner-market(We customize your report according to your research need. Ask our sales team for report customization.)In terms of geography, North America is one of the largest 3D scanners market in which the U.S. is dominating the market due to the high adoption of automotive as well as healthcare sectors in this region. Also, the research and development field is increasing and also modeling operations which are boosting the growth of the 3D scanner market in this region.The taxonomy of the 3D scanner market by its scope and segmentation is as follows:Global 3D Scanner Market: Component Analysis * Hardware * Software * ServicesGlobal 3D Scanner Market: Type Analysis * Portable * Desktop Based * Fixed Mount * Robot MountGlobal 3D Scanner Market: End-User Analysis * Automotive * Healthcare * Aerospace & Defense * Education * Manufacturing * Media & Entertainment * OthersKey Insights from Primary Research * As per our primary respondents, the global 3D scanner market is set to grow annually at a rate of around 7.2%, and the revenue was valued at around USD 2.4 Billion in 2019. * The U.S. held the largest market share in 2019 due to the high adoption of automotive as well as healthcare sectors in this region. * On basis of the “Component” segment, the software segment dominated the global 3D scanner market due to the rise in the adoption of new software upgrades for 3D scanners. * On basis of the “End-User” segment, an automotive segment dominated the global 3D scanner market because it is widely used in automotive for quality control purposes and also for inspection applications. * The presence of well-established players has intensified the industry rivalry, due to which the degree of competition is considerably higher.Related Reports:Optical Fiber Preform Market Research Report, 2020-2026: https://www.fnfresearch.com/optical-fiber-preform-marketVideo Conferencing Market Research Report, 2020-2026: https://www.fnfresearch.com/video-conferencing-marketFiber Optics Market Research Report, 2020-2026: https://www.fnfresearch.com/fiber-optics-market-by-mode-single-mode-multi-1168Lithium-Ion Battery Market Research Report, 2020-2026: https://www.fnfresearch.com/global-lithium-ion-battery-market-by-type-lithium-795About Us:Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.Follow Us LinkedIn: https://www.linkedin.com/company/fnfresearchFollow Us Twitter: https://twitter.com/fnfresearchContact Us:Facts & FactorsA 2108, Sargam,Nanded City,Sinhagad Road,Pune 411041, IndiaUSA: +1-347-989-3985Email: email@example.comWeb: https://www.fnfresearch.comBlog: http://fnfnewsblog.com
For the First Time, Real-World Data is Used to Deliver Real-Time Care Support Information at the Point-Of-CareROCHESTER, Mich., Dec. 01, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has introduced a transformative enhancement to its digital health and communications platform. The new enhancement involves the application of advanced analytics, using machine-learning methods applied to real-world data (RWD), resulting in the accurate delivery of therapeutic support and brand messages to clinicians at critical points in a patient's care journey.This use of patient and scenario modeling that optimizes and automates information delivery at the point-of-care is unprecedented in the industry.The solution creates new opportunities for life science organizations to better support providers as they look to make the best treatment decisions for their patients, especially for those with complex dosing requirements or chronic disease indications. The innovation also enables more messages to be delivered to more physicians whose actions were not previously visible on the platform."Everyone is trying to solve the problem of siloed health data," noted Steve Silvestro, chief commercial officer at OptimizeRx. “Lack of communication between healthcare systems has created a big problem for patients and providers, since often they don’t have all the information they need at crucial moments during the delivery of care. Democratizing data in this way gives life science organizations the ability to communicate directly with providers using an automated, compliant, and data-driven method, and one that is based on care milestones and a patient’s treatment history.”A recent analysis by the Partnership for Health IT Patient Safety reveals how patient outcomes can be impacted by delays and breakdowns in communication during the care delivery process. This is especially evident in specialty and oncology medicine, where OptimizeRx’s RWD evidence-driven approach can help healthcare providers unlock valuable insights for their patients. It can speed time-to-diagnoses and care referrals, as well as prevent delays in treatment and reduce cost in the system, and ultimately allow patients to have a better overall experience with improved outcomes.“The entire healthcare system is focused on data interoperability in order to deliver the most effective care,” said Miriam Paramore, OptimizeRx president. “Data alone doesn’t help, but actionable information does. Given our platform’s access to real-world-data, such as diagnoses, lab results, and procedure details, we can apply our ‘secret sauce’ of AI and machine learning so that the data becomes useful information. We can then deliver this information at the right time, to the right person, and right within their daily e-prescribing workflow. This represents a true breakthrough in our efforts to improve the overall healthcare system for patients and providers alike.” About OptimizeRx OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the US and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.Company Contact Doug Baker, CFO Tel (248) 651-6568 x807 firstname.lastname@example.orgMedia Contact Maira Alejandra, Media Relations Manager Tel (754) 245-7070 email@example.comInvestor Relations Contact Ron Both or Grant Stude CMA Investor Relations Tel (949) 432-7557 firstname.lastname@example.org
AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, today announced that the University of Texas MD Anderson Cancer Center is now an active clinical trial site in its ongoing ReSPECT™ Phase 1 clinical trial, currently supported by the National Cancer Institute (NCI). ReSPECT is a multi-center, dose-finding study evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM). The study will be conducted by MD Anderson’s Department of Neurosurgery with Jeffrey Weinberg, M.D., Professor of Neurosurgery and the Deputy Chair and Vice-Chair of Clinical Operations in The Department of Neurosurgery, as primary investigator.“We are very excited to now have the MD Anderson Cancer Center enrolling patients in the ReSPECT clinical trial,” said Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, Health Services Center at San Antonio and principle investigator of the ReSPECT trial. “Jeffrey and his team are a valuable addition to our efforts to advance RNL as a potential new treatment option for recurrent GBM.”“We are pleased to add Dr Weinberg and the MD Anderson Cancer Center team to our growing list of ReSPECT trial sites,” said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “The company will significantly benefit from the exceptional team of institutions as well as clinical and scientific advisors with whom we are working that all share our dedication to improving the care of GBM patients.”As the Company previously disclosed, the sixth dose escalation cohort of the ReSPECT trial is underway and expected to enroll by the end of 2020. In September 2020, the U.S. Food and Drug Administration granted both Orphan Drug designation and Fast Track designation to RNL for the treatment of patients with glioblastoma. Additional details about the ReSPECT trial are available at clinicaltrials.gov (NCT01906385).About Plus Therapeutics, Inc.Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.Cautionary Statement Regarding Forward-Looking StatementsThis press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop drug candidates currently in its product pipeline; and the Company’s potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.Investor Contact Peter Vozzo Westwicke/ICR (443) 377-4767 Peter.Vozzo@westwicke.comMedia Contact Terri Clevenger Westwicke/ICR (203) 856-4326 Terri.Clevenger@westwicke.com
VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- ParcelPal Technology Inc. (“ParcelPal” or the “Company”), (PKG:CSE) (FSE:PT0) (OTC:PTNYF) is pleased to announce its financial results for the period ended September 30, 2020 (“Q3 2020”), highlighted by continued revenue growth compared to the same period 2019. OverviewIn Q3 2020, the Company continued its operating growth, which was driven by revenue growth of approximately 13% to approximately $1,466,528 (up from $1,299,275 in Q3 2019), which is a record revenue high for Q3 since inception of the Company. Our revenue growth has been driven by our business expansion, in which we continue to sign and retain higher margin customer agreements, ramping up our staffing levels to meet the increase in business, increasing our focus on client diversification, and expanding into new markets. Some highlights of the third quarter include both an increase in our business with Amazon, as well as continued diversification of our customer base and into other areas driven by home meal kits and large retail store chain deliveries. Continuing with this planned trend, the Company had also announced newly executed agreements in the third quarter, including increased business in the flower delivery space, meal kit deliveries and as of last week a nationwide specialty pharmacy services and solutions company.In Q3, the Company also experienced certain one-time expenses, including costs related to the positioning of the Company for greater success moving forward in the near and longer term, as exhibited by our first ever profitable month in October 2020. Certain of these expenses included expansion into new market costs, additional fleet acquisitions, personnel changes, shifting from B2C to B2B sales, securing a primary listing of our securities on the OTCQB, and accruing expenses related to becoming an SEC compliant filer. The additional cost incursions increased our net loss for the quarter by 52% to $1,095,404 (compared to $721,727 in Q3 2019). With this expansion and certain strategic changes has come higher short term costs; however, with many of these temporary costs behind us, we believe the Company will see continued improvement in profitability and operating margins in Q4 and beyond.CEO Rich Wheeless stated, "I am very pleased that in this third quarter we made significant headway in executing our shift and focus into B2B sales, while simultaneously with increased revenues. As noted above, in this third quarter we were faced with increased (including a number of temporary) expansion and strategic costs, as well as having incurred certain previously unaccrued costs by prior management. With all of this being said, we are in a strong position to have a solid Q4 and to remain strong heading into the 2021 calendar year. We will continue to execute on our effective growth plan, which is a combination of organic growth and potential acquisitions, if and as they arise and add value to our Company and for our shareholders. I am excited about the future of this Company, and know that our efforts are working, as demonstrated by the recent announcement that October 2020 was our first profitable month, ever. Further, I hope to announce additional profitable months as we continue to scale. I look forward to providing new and additional information in upcoming quarters.”Q3 2020 Financial Highlights: * Revenue growth of nearly 13% to $1,466,528 (up from $1,299,275 in Q3 2019). Note: this was a record revenue high for Q3 since inception of the company. Note: the Company’s revenue for the nine months ended September 30, 2020 is $4,012,441 compared to $2,841,162 (an increase of 41%) during the nine months ended September 30, 2019. * Decreased expenses on non-profitable marketing and promotions to $16,655 (Q3 2019 - $270,876) in an effort to conserve cash and focus on operational growth. * Consulting fees in Q3 decreased to $39,295 (Q3 2019 - $114,761) as the Company reduced such expenses to reduce overhead costs and conserve cash in the current period. We expect these consulting fees to be significantly reduced further on a going forward basis. * Share-based compensation in Q3 decreased to $34,827 (Q3 2019 - $152,895) due to fewer stock options and other stock based compensation being granted during the current period. * During the three months ended September 30, 2020 the Company had a net loss of $1,095,404 compared to $713,241 (an increase of 52%) during the three months ended September 30, 2019. Note: the Company’s net loss for the nine months ended September 30, 2020 is $2,817,710 compared to $3,970,290 (a decrease of 29%) during the nine months ended September 30, 2019. OutlookThe Company's strategic priorities for the remainder of fiscal 2020 include: * Continued development of the ParcelPal product through a series of build-measure-learn iterations and moving into new verticals. * Building an exceptional and world-class brand with a focus on high quality content and services. * Increasing the number of customers and users using the ParcelPal platform. * Using data, technology, and inbound selling to ramp up sales and revenue generation. * Continued expansion into large markets in Canada, and also planning the Company’s entry into the United States market. The Company's complete financial results are available in its unaudited financial statements and Management's Discussion and Analysis for the period ended September 30, 2020, each of which have been filed with Canadian securities regulators at www.sedar.com.About ParcelPal Technology Inc.ParcelPal is a leader in the growing technology and logistics industry. ParcelPal seamlessly connects consumers to businesses, where they have access to the goods they love, anytime, anywhere. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour or the same day. The Company offers on-demand delivery of merchandise from leading retailers, restaurants, medical marijuana dispensaries and liquor stores in Vancouver, Calgary, Toronto and soon in other major cities Canada-wide.ParcelPal Website: www.parcelpal.comThe Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.CSE – Symbol: PKG FSE – Symbol: PT0 OTC – Symbol: PTNYFContact: re: Investor Inquiries - email@example.comForward Looking InformationThis news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal. Forward looking statements are often identified by terms such as "will", "may", "should", “intends”, "anticipates", "expects", “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.The Company cannot guarantee that any forward looking statement will materialize and the reader is cautioned not to place undue reliance on any forward looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement. The forward looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.
TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that recently acquired subsidiary, Transforming Systems, has completed a multi-year contract with Bedfordshire, Luton and Milton Keynes Integrated Care System (“BLMK” or the “ICS”) to deploy its proprietary SHREWD Resilience, Action and Vantage products. Transforming Systems first connected with the Bedfordshire, Luton & Milton Keynes system in mid-2019 as they neighbour existing Transforming Systems clients in Hertfordshire & West Essex. BLMK sought a digital system that would provide oversight of their urgent and emergency care pathway and determined the SHREWD portfolio was an ideal solution to address their needs.Located in the Midlands and East regions of the United Kingdom, the Bedfordshire, Luton and Milton Keynes ICS is a regional healthcare body responsible for the care of a population of 1,000,000 individuals. An ICS or “Integrated Care System” constitutes NHS organisations, in partnership with local councils and others, taking collective responsibility for managing resources, delivering NHS standards, and improving the health of the population they serve.The BLMK deployment will include 2 acute trusts, Milton Keynes University Hospital NHS Foundation Trust and Bedfordshire Hospitals NHS Foundation Trust, together with a collective of CCGs, ambulance & community trusts and 4 local county councils. The combination of the 3 SHREWD modules will aim to improve data visibility across their Integrated Care System and help drive efforts to maintain the best possible patient care through their hospitals and into the community.The BLMK ICS’s development into an Integrated Care System from a Sustainability and Transformation Partnership (STP), comprising 16 partners from across the region, further emphasizes the need for digital patient and operational visibility solutions, as this regional group of organizations will work in deeper collaboration to plan and manage the resources and delivery of care throughout the area. The ICS’ goal has been to gain a consistent view of activity and pressure points, which will be accomplished using the SHREWD Resilience, and then to invigorate their surge response, using SHREWD Action. The SHREWD Vantage module will offer an at-a-glance summary view of the ICS’ entire patch and is aimed at senior managers and executives.Taken together, implementation of the SHREWD suite of solutions will afford the ICS with a regional, real-time, data-driven view of their demand and capacity, across organizations, providing insight into the performance and delivery of care, to enable the more efficient and effective load balancing and allocation of resources, across the BLMK health economy.“We have been working towards this partnership for some time and we are delighted to now move forward with Bedfordshire, Luton and Milton Keynes to help drive their efforts to maintain the best possible patient care through their hospitals and into the community,” said Lisa Riley, Vice President of Strategic Product and Partnership Development, Transforming Systems. “We are committed to supporting them to improve visibility and oversight of their urgent and emergency care pathways by creating a consistent view of activity and pressure across the whole health economy, using our SHREWD Resilience, Action and Vantage modules.” “The market is clearly demonstrating the significant demand for products that offer regional health authorities and governments access to data visibility solutions to help manage operational efficiencies and resource allocation, optimizing care delivery for all patients,” said Dan Matlow, CEO of VitalHub Corp. “The SHREWD platform continues to demonstrate its strength in serving this need, as it extends our reach across the UK healthcare market. As COVID-19 continues to accelerate the adoption of real-time, regional operational visibility solutions, we look forward to continuing to deepen our presence and growth in this market.”ABOUT TRANSFORMING SYSTEMS HEALTH INFORMATICS INC.In 2015, Transforming Systems began commercializing their solutions to help the NHS solve a fundamental challenge surrounding lack of access to real-time information across its multitude of services. Developed over the course of a 6-year R&D process, Transforming Systems’ product portfolio, SHREWD, aims to solve the challenge of capturing and transforming high quality data on fluctuating scales, from varying sources.The product portfolio facilitates secure, real-time data collection, analysis and forecasting, at a price that is accessible to all health and social care commissioners. Once captured, the SHREWD Platform empowers NHS teams to determine actionable insights from a wide range of healthcare data, leading to improved organizational efficiencies and resource utilization, ultimately aiming to improve the delivery of patient care.ABOUT VITALHUBSoftware for Health and Human Services providers designed to simplify the user experience & optimize outcomes.VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services. VitalHub solutions span the categories of Electronic Health Record (EHR), Case Management, Care Coordination, Patient Flow & Operational Visibility, and DOCit Mobile Apps.The Company has a robust two-pronged growth strategy, targeting organic growth opportunities within its product suite, and pursuing an aggressive M&A plan. Currently, VitalHub serves 275+ clients across Canada, USA, UK, Australia, Qatar, and Latvia. VitalHub is based in Toronto, Canada, with an offshore development hub in Sri Lanka. The Company is publicly traded on the TSX Venture Exchange under the symbol “VHI”.CAUTIONARY STATEMENTThis press release includes forward-looking statements regarding the Corporation and its business, which may include, but is not limited to, statements with respect to the appointment of a new directors. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity and are based on assumptions and subject to risks and uncertainties. Although the management of each entity believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the technology industry, failure to obtain regulatory or shareholder approvals, market conditions, economic factors, the equity markets generally and risks associated with growth and competition. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.CONTACT INFORMATIONDan Matlow Chief Executive Officer, Director (416) 727-9061 firstname.lastname@example.org
Concerns over a near-term slowdown in the data center business shouldn't have investors worried.
Corporate event to provide clinical update for CG-806 in AML and B-cell CancersPoster Presentations for CG-806 and APTO-253 are scheduled for December 5th and 6th at 2020 ASH Annual Meeting and Exposition SAN DIEGO and TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company management team will provide a corporate update on Sunday, December 6th, at 2:00 PM PT, in conjunction with participation at the 2020 ASH Annual Meeting. The event will include the current clinical status of CG-806, Aptose’s oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor currently in two Phase 1 a/b trials, one in patients with relapsed or refractory acute myeloid leukemia (AML) and another in patients with relapsed or refractory B cell malignancies, as well as a review of APTO-253, a first-in-class small molecule MYC inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).Aptose Corporate Update DetailsDate & Time: Sunday, December 6, 2020, 2:00 PM PTParticipant Webcast Link: http://public.viavid.com/index.php?id=142523Participant Dial-in: Toll Free: Toll/International: Conference ID: 1-877-407-9039 1-201-689-8470 13713479 The slides will be available on Aptose’s website here and a recording of the presentation will be archived shortly after the conclusion of the event. As announced previously, early clinical data, along with certain preclinical data for CG-806 and APTO-253, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, being held virtually Saturday, December 5 – Monday, December 7, 2020. The posters will be available on the presentations page of Aptose website here.Poster Presentation DetailsAbstract 1042: A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS Poster Session Date & Time: Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT Session Name: 616\. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster IAbstract 1174: Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models Poster Session Date & Time: Saturday, December 5, 2020, 7:00 AM - 3:30 PM PT Session Name: 625\. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster IAbstract 2228: A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin’s Lymphomas Poster Session Date & Time: Sunday, December 6, 2020, 7:00 AM - 3:30 PM PT Session Name: 642\. CLL: Therapy, excluding Transplantation: Poster IIAbout AptoseAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: CG-806, an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1 trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1 trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only known clinical stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).For further information, please contact: Aptose Biosciences Inc. Greg Chow Executive Vice President, CFO 858-926-2730 email@example.com SMP Communications Susan Pietropaolo 201-923-2049 firstname.lastname@example.orgLifeSci Advisors, LLC Dan Ferry, Managing Director 617-430-7576 Daniel@LifeSciAdvisors.com
SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appointment of Alan Sandler, M.D., to the newly created position of President, Head of Global Development, Oncology, where he will lead global oncology development and related enabling functions to support the Company’s development activities. Dr. Sandler was most recently the Senior Vice President and Global Head of Product Development Oncology at Genentech, a member of the Roche Group. He will report to Dr. Samantha Du, Chief Executive Officer, and serve on the executive team. “We are delighted to welcome Alan to Zai Lab as we continue to expand globally and strengthen our R&D leadership,” said Dr. Samantha Du, Founder, Chairwoman and CEO of Zai Lab. “Throughout his distinguished career, Alan has made significant contributions as a respected leader in the oncology community, both in industry and through his clinical practice and academic research. Alan has played a key role in the development of many innovative oncology therapies. We look forward to his leadership of our oncology franchise as we advance towards our goal of becoming a leading global biopharma company.”“I’m very excited to be joining Zai Lab, given its robust pipeline of innovative clinical compounds,” said Dr. Sandler. “I look forward to accelerating the development of Zai’s extensive and differentiated pipeline of oncology compounds, guide them through regulatory review, and bring them as quickly as possible to patients in need in China and around the world. I am also excited about working to identify additional product candidates to further expand Zai’s oncology portfolio.”Dr. Sandler brings nearly 30 years of oncology and drug development experience across industry and academia. During his tenure at Genentech/Roche, he led the teams responsible for the global development and regulatory approval of several innovative medicines, most recently Tecentriq®. Prior to joining Genentech/Roche, Dr. Sandler served as Professor and Chief of Hematology/Oncology at Oregon Health and Science University. Previously, he served on the faculties of the medical schools of Indiana University and Vanderbilt University. He holds a Doctor of Medicine degree from Rush Medical College. Dr. Sandler completed his training in internal medicine and a fellowship in medical oncology at Yale-New Haven Medical Center. He has published over 300 peer-reviewed publications, articles, abstracts and book chapters.About Zai Lab Zai Lab (NASDAQ:ZLAB; HKEX: 9688) is an innovative commercial-stage biopharmaceutical company focused on bringing transformative medicines for cancer and infectious and autoimmune diseases to patients in China and around the world. We aim to address significant unmet medical needs in large, fast-growing segments of the pharmaceutical market. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and drug candidates. We have also built an in-house team with strong drug discovery and translational research capabilities and are establishing a pipeline of proprietary drug candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.For more information, please contact:ZAI LAB CONTACTS:Zai Lab Billy Cho, CFO +86 137 6151 2501 email@example.comMedia: Ryo Imai / Robert Flamm, Ph.D. Burns McClellan, on behalf of Zai Lab 212-213-0006 ext. 315 / 364 firstname.lastname@example.org / email@example.comInvestors: Pete Rahmer / Mike Zanoni Endurance Advisors, on behalf of Zai Lab 415-515-9763 / 610-442-8570 firstname.lastname@example.org / email@example.comZai Lab Limited
SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer's disease. ATH-1017 is a small molecule therapeutic designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in the central nervous system, in order to promote brain health and function. The Phase 2 ACT-AD clinical trial (www.act-adtrial.com, clinicaltrials.gov identifier NCT04491006) will enroll up to approximately 75 individuals with mild-to-moderate Alzheimer’s disease in the United States and Australia. Similar to the company’s LIFT-AD trial, participants in the ACT-AD will be randomized across two dose groups and one placebo group on a 1:1:1 basis to receive a daily subcutaneous injection of ATH-1017 or placebo over a treatment course of 26 weeks and will be evaluated for improvement in cognition, global, and functional assessments comparing treatment arms to placebo. ACT-AD will also use electroencephalogram (EEG), to measure quantitative electroencephalogram (qEEG), and Event-Related-Potential (ERP P300), a functional measure of working memory processing speed and executive function. Results from the ACT-AD trial may provide Athira with supportive information that can help optimize the LIFT-AD as a potentially pivotal trial.“This Alzheimer’s treatment approach is innovative and novel. As part of the study design, the use of qEEG and ERP 300 as physiological outcome measures and indicators of improved function in brain networks could be highly valuable to the field as a whole, ” said Charles Bernick, MD, MPH, Clinical Professor, University of Washington School of Medicine, Department of Neurology, Co-investigator, University of Washington Alzheimer’s Disease Research Center and Director of Clinical trials, UW Medicine Memory & Brain Wellness Center."The initiation of our second late-stage study for ATH-1017 represents a significant milestone for Athira as we advance our clinical program to treat this area of immense medical need," said Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira. "Athira’s novel treatment approach is agnostic to the underlying disease pathology of Alzheimer’s and other dementias. It focuses on network recovery and information transmission in the brain, which has the potential to improve clinical outcomes for patients. Our goal, with both this ACT-AD study and the LIFT-AD study, is to demonstrate the clinical utility of this promising agent to treat Alzheimer’s disease and preserve cognitive health."About ATH-1017 ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function, in order to impact neurodegeneration and regenerate brain tissue. In addition to Alzheimer’s disease, ATH-1017 is designed to address the broader dementia population, including Parkinson’s disease dementia. Athira’s completed Phase 1a/b clinical trials of ATH-1017 for the treatment of Alzheimer's disease established that the treatment was generally well tolerated at all tested doses. Measures evaluating brain function with quantitative electroencephalogram (qEEG) also produced a strong suite of translational data. Additionally, a statistically significant improvement in Event-Related Potential (ERP) P300 latency, an objective measure of working memory processing speed, was noted in patients with Alzheimer’s disease following multiple dose treatments with ATH-1017 compared with those receiving placebo.About Athira Pharma, Inc. Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.Forward-Looking Statements This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding ATH-1017 as a potential treatment for Alzheimer’s and other dementias; Athira’s platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof; anticipated design of planned clinical trials; expectations regarding the potential efficacy and commercial potential of Athira’s product candidates, including ATH-1017; the anticipated presentation of data; the results of Athira’s research and development efforts and Athira’s ability to advance its product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary data for Athira’s ATH-1017 product candidate from the Phase 1a/b trials will not continue or persist; cessation or delay of any of the ongoing clinical trials and/or Athira’s development of ATH-1017 may occur; future potential regulatory milestones of ATH-1017, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; the impact of the COVID-19 pandemic on Athira’s business; Athira’s research and development efforts and its ability to advance product candidates into later stages of development may fail; any one or more of Athira’s product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; as well as the other risks detailed in Athira’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.Investor & Media Contact: Julie Rathbun Julie.firstname.lastname@example.org 206-769-9219
PHOENIX, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (CSE: TILT) (OTCQB: TLLTF), a provider of business solutions to the global cannabis industry, announced today the completion of its previously announced sale (the “Blackbird Sale”) of all of the membership interests of Yaris Acquisition, LLC (dba. Blackbird) (“Blackbird”) by Baker Technologies, Inc. (“Baker”), an indirect wholly owned subsidiary of the Company, to Slam Dunk, LLC (the “Buyer”), a Nevada limited liability corporation controlled by Tim Conder, TILT’s former Chief Operating Officer and a member of the board of directors of the Company (the “Board”). In accordance with the terms of the securities purchase agreement (the “Agreement”), Mr. Conder resigned from his position as the Chief Operating Officer of the Company upon the closing of the Blackbird Sale. “Jupiter, Commonwealth Alternative Care, and Standard Farms are all synergistic, cashflow positive businesses with ample runway for reinvestment and future growth and now is the right time to give them the additional resources they need,” said Gary Santo, President of TILT. “Given the uncertainty and investment required to build Blackbird into a value contributing entity, we believe that completing this asset divestiture in order to focus our time and capital on TILT’s fastest growing and most profitable businesses creates immediate value to shareholders.”Mr. Santo continued, “We cannot thank Tim enough for all that he has done during his tenure at TILT, and we wish him well as he steps out on his own to build Blackbird.” Pro-Forma Consolidated Financial Information Excluding Blackbird Three Months EndedNine Months Ended Reported Pro-forma excluding BlackbirdReported Pro-forma excluding Blackbird Sep 30, 2020 Sep 30, 2020 Sep 30, 2020 Sep 30, 2020 Revenue $40,439 $39,084 $121,453 $116,144 Gross Margin %, Before FV Adj. 30.3% 31.3% 28.8% 30.5% Gross Margin %, After FV Adj. 46.6% 48.2% 39.2% 41.4% Total Operating Expenses $17,048 $14,006 $51,470 $43,658 Net Income (Loss) ($4,617) ($1,428 ($13,610) ($6,332) EBITDA, Non-IFRS $7,451 $10,019 $13,800 $20,937 Adjusted EBITDA, Non-IFRS $2,764 $5,409 $5,667 $12,653 Key Transaction Terms * Total consideration (the “Consideration”) payable for the Blackbird Sale was approximately US$15,000,000 which such figure is unaudited and subject to further reconciliation, and consists of: ° a convertible senior secured promissory note (the “Promissory Note”) in the principal amount of $10,000,000 (the “Base Principal Amount”); ° the assumption of various liabilities, which were approximately $5,000,000; and ° the Promissory Note is secured by a perfected security interest in all of the assets of Blkbrd Software LLC. * Interest shall accrue and be payable on November 30, 2023 (the “Maturity Date”) on any unpaid Base Principal Amount and unpaid interest thereon outstanding from time to time at a rate of: ° ten percent per annum for the period commencing on November 30, 2020 and ending on November 30, 2021; ° eleven percent per annum for the period commencing on November 30, 2021 and ending on November 30, 2022; and ° twelve percent per annum for the period commencing on November 30, 2022 and ending on the Maturity Date. * Upon the satisfaction of certain terms and conditions outlined in the Agreement, for a period of six months following the closing of the Blackbird Sale, Baker may advance to the Buyer an amount equal up to an aggregate of US$1,000,000 (the “Additional Funding Amount”), with any such advances increasing the principal balance outstanding under the Promissory Note. ° Interest on the Additional Funding Amount shall accrue at a rate of 15% per annum over the first twelve months, 16% over the second twelve months and 17% over the final twelve months. * The Base Principal Amount and, if any, Additional Funding Amount may be converted in whole or in part into membership interests of the Buyer or other preferred or common equity interest of the Buyer, at the discretion of Baker, based on the fair market value of such interests, provided that the conversion is not into more than forty-nine percent of the then outstanding membership interests of the Buyer.The Blackbird Sale was considered and unanimously approved by the Board (with Tim Conder abstaining from the vote due to him being a related party). In connection with its decision to unanimously approve the Blackbird Sale, the Board retained Cormark Securities Inc. (“Cormark”) to act as financial advisor to the Company in connection with the Blackbird Sale. Under the supervision of the Company, Cormark solicited interest in a potential transaction from a number of parties which were evaluated based on a number of factors. In connection with entry into the Agreement, Cormark provided an opinion (the “Opinion”) to the Board that, as at November 18, 2020 and subject to the assumptions, limitations and qualifications contained in the Opinion, the Consideration is fair from a financial point of view to the Company. In order to provide the Opinion, Cormark relied upon, without limitation, the following methodologies: (i) reference methodologies including both the strategic alternatives available to TILT with respect to Blackbird and the history of the acquisition of Blackbird; and (ii) core methodologies applying the relative value approach, precedent transaction approach and discounted cash flow approach.The Blackbird Sale was not subject to regulatory approval or approval by the shareholders of TILT. The Company did not file a Material Change Report in connection with the Blackbird Sale more than 21 days before the closing date of the Blackbird Sale as the closing conditions related to the Blackbird Sale had been satisfied and the Company wished to close the Blackbird Sale on an expedited basis for sound business reasons. The Agreement, including the form of Promissory Note, is available on the Company’s SEDAR profile at www.sedar.ca.About TILT TILT helps cannabis businesses build brands. Through a portfolio of companies providing technology, hardware, cultivation and production, TILT services brands and cannabis retailers across 35 states in the U.S., as well as Canada, Israel, Mexico, South America and the European Union. TILT’s core businesses include Jupiter Research, LLC, a wholly owned subsidiary and leader in the vaporization segment focused on hardware design, research, development and manufacturing; and cannabis operations Commonwealth Alternative Care, Inc. in Massachusetts and Standard Farms, LLC in Pennsylvania. TILT is headquartered in Phoenix, Arizona. For more information, visit www.tiltholdings.com.Forward-Looking Information This news release contains forward-looking information based on current expectations. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward looking information may include, without limitation, the anticipated economic benefits of the Blackbird Sale to the Company, the opinions or beliefs of management, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of TILT, and includes statements about, among other things, future developments, the future operations, strengths and strategy of TILT. Generally, forward looking information can be identified by the use of forward looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. These statements should not be read as guarantees of future performance or results. These statements are based upon certain material factors, assumptions and analyses that were applied in drawing a conclusion or making a forecast or projection, including TILT’s experience and perceptions of historical trends, the ability of TILT to maximize shareholder value, current conditions and expected future developments, as well as other factors that are believed to be reasonable in the circumstances.Although such statements are based on management’s reasonable assumptions at the date such statements are made, there can be no assurance that they will be completed on the terms described above and that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Accordingly, readers should not place undue reliance on the forward-looking information. TILT assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by applicable law.By its nature, forward-looking information is subject to risks and uncertainties, and there are a variety of material factors, many of which are beyond the control of TILT, and that may cause actual outcomes to differ materially from those discussed in the forward-looking statements.For additional information regarding forward-looking statements and their related risks, please refer to the “Risk Factors and Uncertainties” section in the Management Discussion and Analysis of the Company for the quarter ended on September 30, 2020, which is available on the Company’s SEDAR profile at www.sedar.com.Non-IFRS Financial and Performance Measures In addition to providing financial measurements based on International Financial Reporting Standards (“IFRS”), the Company provides additional financial metrics that are not prepared in accordance with IFRS. Management uses non-IFRS financial measures, in addition to IFRS financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate the Company’s financial performance. These non-IFRS financial measures are EBITDA and Adjusted EBITDA. Management believes that these non-IFRS financial measures reflect the Company’s ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business, as they facilitate comparing financial results across accounting periods and to those of peer companies. Management also believes that these non-IFRS financial measures enable investors to evaluate the Company’s operating results and future prospects in the same manner as management. These non-IFRS financial measures may also exclude expenses and gains that may be unusual in nature, infrequent or not reflective of the Company’s ongoing operating results. As there are no standardized methods of calculating these non-IFRS measures, the Company’s methods may differ from those used by others, and accordingly, the use of these measures may not be directly comparable to similarly titled measures used by others.Accordingly, these non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.EBITDA and Adjusted EBITDA EBITDA and Adjusted EBITDA are financial measures that are not defined under IFRS. The Company uses these non-IFRS financial measures, and believes they enhance an investor’s understanding of the Company’s financial and operating performance from period to period, because they exclude certain material non-cash items and certain other adjustments management believes are not reflective of the Company’s ongoing operations and performance. The Company calculates EBITDA as net income (loss), plus (minus) income taxes (recovery), plus (minus) finance expense (income), plus depreciation and amortization expense. Adjusted EBITDA excludes certain one-time, non-cash or non-operating expenses, as determined by management, including stock compensation expense, business acquisition expense, debt issuance costs, severance, unrealized (gain) loss on changes in fair value of biological assets and fair value changes in biological assets included in inventory sold.Reconciliations of Non-IFRS Financial and Performance Measures Adjusted EBITDA is reconciled to Net Loss in the section labelled “Reconciliation of Net Income (Loss) to Non-IFRS Measures” in the Management Discussion and Analysis of the Company for the quarter ended on September 30, 2020, which is available on the Company’s SEDAR profile at www.sedar.com.Investor Relations Contact:Taylor Allison email@example.com Media Contact:Ellen Mellody Ellen@mattio.com 570-209-2947 The CSE has neither approved nor disapproved the contents of this news release.
* NexTech is growing rapidly across Asia through both incoming inquiries and in-network connections looking for enhanced augmented reality and virtual experiences * The Company is building out a team of strategic partners to provide 24/7 service to clients in the Asia Pacific Market * Signs 7-New Channel partnerships; goSMAC, MedSurge Tek In, VITO DESIGN & COMMUNE, VITO DESIGN, Sports Coalition Singapore, Curriculum Lab and Eugene Liew * Partners accelerate the company’s push into the $229B MICE industry and entrance into Asia’s $35B e-learning marketVANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), a leading provider of virtual and augmented reality (AR) experience technologies and services for eCommerce, education, conferences and events today announced that it has entered into seven additional strategic channel partnerships bringing the total for the Asia Pacific region to eight. These partner agreements support both the $35B e-learning market and $229B MICE industries, two target sectors that NexTech is focusing on in the Asia Pacific market expansion.These partnerships further add to NexTech’s rapidly growing channel and strategic partner portfolio, following the announcement of its collaboration with South Korea’s largest events coordinator and event hall, Coex, early last month. With these additional agreements in place NexTech now has representation in Korea, Malaysia, Philippines and Singapore, marking a major expansion of the reach of NexTech’s AR Solutions sales efforts, including; AR for eCommerce, AR for hybrid events, AR labs for education and it’s 3D/AR advertising network.These partners will be able to support, sell, design, build and deliver NexTech’s suite of customizable AR and virtual experience solutions, to a market that is actively seeking new solutions for hybrid events and education settings. These are just the first group of partners to help provide 24/7 tech support, making the NexTech solution and services accessible anytime, from anywhere.“The response to NexTech’s AR and virtual experience offerings has been overwhelmingly positive; we have 7 quotes in the market in just the first 30 days. Every other day we’re connecting with potential partners inside and outside of our networks, who are particularly interested in the AR component but who are also seeing the additional value of our comprehensive virtual experiences,” Yau Boon Lim, President and Managing Director, Asia Pacific at NexTech AR. “Our strategy for growth and scaling has always been on building an ecosystem of channel partners in key industries that are high growth and can benefit in the short and long term from these technologies. We are confident that this first group of eight will be an integral part in helping us scale Southeast Asia, and they are the first of many more strategic partnerships that will emerge through our efforts in this market.”A report by Allied Market Research notes that the Asia Pacific MICE industry generated revenue of $229 billion in 2017 and is expected to grow at a CAGR of 8.6% to reach $441.1 billion by 2025, providing a significant opportunity for virtual and hybrid events. In the education industry, e-learning was evaluated as a $35 billion market in 2019 and is expected to surpass $90 billion by 2026.“We are thrilled to have Yau Boon sign up such an impressive group of partners so quickly which speaks to the interest in our technology and products. These eight partners are a key first step for our expansion within the Asia Pacific Market. We are growing very rapidly in North America and the EMEA regions, and plan to continue this fast growth with expansion into the Asia Pacific market. We believe NexTech should be accessible 24/7 and through these partnerships, we are able to do just that. The education and MICE industries represent significant growth opportunities and with the support of our growing list of partners, we believe we’ll be able to get in front of the right decision makers, which will drive the rapid adoption of our products and services and will continue to drive our revenue growth in 2021 and beyond” said Evan Gappelberg, CEO of NexTech AR.NexTech is continuing to connect with and establish channel partnerships throughout Asia Pacific. To learn more about its services or to become a partner, please click here.About NexTech AR NexTech is one of the leaders in the rapidly growing Augmented Reality market estimated to grow from USD $10.7B in 2019 and projected to reach USD $72.7B by 2024 according to Markets & Markets Research; it is expected to grow at a CAGR of 46.6% from 2019 to 2024.The company is pursuing four verticals: Virtual Conference Platform: An advanced Augmented Reality and Video Learning Experience Platform for Events, is a SaaS video platform that integrates Interactive Video, Artificial Intelligence and Augmented Reality in one secure platform to allow enterprises the ability to create the world’s most engaging virtual event management and learning experiences. Automated closed captions and translations to over 64 languages. According to Grandview Research the global virtual events market in 2020 is $90B and expected to reach more than $400B by 2027, growing at a 23% CAGR. With NexTech’s Virtual Conference Platform having augmented reality, AI, end-to-end encryption and built in language translation for 64 languages, the company is well positioned to rapidly take market share as the growth accelerates globally.ARitize™ For eCommerce: The company launched its SaaS platform for webAR in eCommerce early in 2019. NexTech has a ‘full funnel’ end-to-end eCommerce solution for the AR industry including its Aritize360 app for 3D product capture, 3D/AR ads, its Aritize white label app it’s ‘Try it On’ technology for online apparel, 3D and 360-degree product views, and ‘one click buy’.ARitize™ 3D/AR Advertising Platform: Launched in Q1 2020 the ad platform will be the industry's first end-to-end solution whereby the company will leverage its 3D asset creation into 3D/AR ads. In 2019, according to IDC, global advertising spend will be about $725 billion.ARitize™ Hollywood Studios: The studio is in development producing immersive content using 360 video, and augmented reality as the primary display platform.To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.For further information, please contact: Evan Gappelberg Chief Executive Officer firstname.lastname@example.org The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
* Revenue of CAD$7.9 million – an increase of 7200% from CAD$108,346 for the same time last year; * Moved from manually pre-rolling to fully automated process which resulted in improved margins mainly reflected in calendar 2020 resulting in blended margins of 23% for the fiscal year end. * Pre-roll brands saw robust demand throughout the pandemic. Icanic’s premium pre-roll brands have been sold to over 380 licensed retailers in California. * Well positioned to leverage newly legalized States via licensing opportunities. * The Company currently has its manufacturing headquarters in Oakland, California; cultivation facility in Sacramento, California; and a manufacturing kitchen and cultivation in North Las Vegas, Nevada. * Icanic Brands is fully funded for the expansion of a new California manufacturing headquarters located in Concord, California which will house Icanic’s 2nd automated pre-roll machine which will be put into production in Q1-2021, resulting in a significant increase in overall production capacity.VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“Icanic Brands” or the “Company”), a multi-state brand operator of premium Cannabis brands in California and Nevada, today reports its financial results for the period ended July 31st, 2020. All currency references used in this news release are in Canadian currency unless otherwise noted.Management Commentary Mr. Brandon Kou, CEO of Icanic commented, “I am proud of our California and Nevada teams for their efforts this quarter and through-out the year during an unprecedented time of difficulty due to the global pandemic. Unfortunately, we witnessed many businesses including some of our peers’ struggle and not make it through this very tough time. The fact that we were able to significantly grow revenue while netting over $560,000 in positive adjusted EBITDA is a true testament to our hard-working team. For our Company, 2020 was always meant to be a year to solidify our company's foundation in preparation for our future while trying to meet the increasing demand for our products including our Ganja Gold Tarantula, one of the category leaders in the pre-roll space. With the introduction of our three-pillar foundation focusing on technology/manufacturing, vertical integration and our sales platform, we have successfully positioned ourselves for a tremendous year of growth ahead."Summary of 2020 Developments: * In March, Icanic launched the Taylor’s pre-roll brand in California to a uniquely, robust market - California experienced significant uptick in cannabis sales during the state wide lockdown and Icanic’s pre-roll sales were a direct beneficiary. * The vertical integration achieved by Icanic has been able to reduce target costs of manufacturing pre-rolls by 80% via the use of a proprietary pre-roll manufacturing system. * In September, Icanic announced it had closed a private placement for aggregate proceeds of $2,000,000. * In November, Icanic commenced construction on its soon to be California headquarters and manufacturing facility and will be relocating to a new 6,650 square foot premises in Concord, California (approximately 20 miles from the current Oakland facility).Outlook: * Immediately leverage positioning in California for strategic and accretive acquisitions. * Launch of additional Ganja Gold SKUs in Q1-2021. * Launch of Ganja Gold products in the Nevada market leveraging existing vertically integrated infrastructure in Q1-2021. * Leverage vertical integration and manufacturing process to officially launch white-label business in H1-2021.About Icanic Brands Company, Inc.Icanic Brands Company, Inc. is a leading cannabis branded products manufacturer based in California & Nevada, the largest and most competitive cannabis markets in the world. The company’s mission is to make cannabis safe and approachable - that starts with manufacturing high-quality products delivering consistent experiences.For more information, please visit the company’s website at: www.icaninc.com.About Ganja Gold Ganja Gold, Inc., a wholly-owned subsidiary of Icanic Brands Company, Inc. (CSE: ICAN, OTCQB: ICNAF), is the premier brand of infused pre-rolls in the state. Ganja Gold focuses on using only the best available flower and concentrates with state of the art proprietary technology to create connoisseur level pre-rolls unseen in the marketplace. With our flagship Tarantula™, Ganja Gold continues to set the bar in quality and experience.For more information about Ganja Gold, visit their website at www.ganjagold.comICANIC BRANDS COMPANY INC.Per:“Brandon Kou” Chief Executive Officer For further information about Icanic Brands, please contact the Company at: Email: email@example.comThe CSE does not accept responsibility for the adequacy or accuracy of this release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Canada’s largest community credit union implements cloud-based platform to manage its commercial loan lifecycleTORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ: NCNO), a pioneer in cloud banking and digital transformation solutions for the global financial services industry, and Accenture (NYSE: ACN) have supported Vancity, Canada’s largest community credit union, in evolving its commercial lending business through the implementation of the nCino Bank Operating System®. With over CA$28.2 billion in assets and more than half a million members, Vancity sought an agile technology to grow its commercial lending business and replace a 15-year-old legacy system. The credit union selected the nCino Bank Operating System, an end-to-end cloud-based platform that manages the entire loan lifecycle — including origination, loan reviews, renewals and modifications — eliminating the need to combine various point solutions.Working alongside teams from Vancity and nCino, Accenture helped implement the nCino platform on time and budget, despite the project occurring in the midst of the COVID-19 pandemic — which made the cloud-based nature of the platform particularly important, as Vancity’s members and employees shifted to a remote work environment.In addition to benefitting Vancity’s commercial loan book, the nCino platform is helping the credit union align processes across lines of business, automate tasks and streamline workflows. Because the nCino Bank Operating System is flexible and configurable, Vancity can continue to customize processes as they see fit to best suit their evolving needs.“By adopting nCino for our commercial lending operations, we’ve embraced a cloud-based technology with regular updates and releases that will grow along with us and help us remain competitive and agile,” said Nez Aquino, chief risk officer at Vancity. “We see nCino as an incredible value-add to our organization, not only from a platform standpoint, but also as partners along our digital transformation journey.”“Digital transformation is top-of-mind for commercial banks of all sizes and particularly credit unions as they embrace changing customer dynamics, and deal with aging legacy systems and the pressure to compete in a challenging environment,” said Robert Vokes, Accenture’s Financial Services practice lead in Canada. “Vancity’s decision to evolve its operations and streamline various businesses with nCino’s cloud-based platform will help them deliver an improved, tailored experience that meets the evolving expectations of members and employees. This is a great example of the scalability of nCino’s platform and the deep industry expertise and talents of our people to bring it alive with our clients.”“Vancity is a great Canadian brand and a real leader in the credit union space, and they should be very proud of how they’ve helped to develop the communities they serve,” said Cam Sterrett, area vice president and general manager – Canada at nCino. “With nCino, Vancity has put a foundational system in place that will give them the ability to grow their member-facing digital front end and further fulfill their mission of improving their members’ financial well-being. We very much appreciate the great work our organizations, alongside Accenture, have been able to do together so far and look forward to expanding these relationships into the future.”About nCino nCino (NASDAQ: NCNO) is the worldwide leader in cloud banking. The nCino Bank Operating System® empowers financial institutions with scalable technology to help them achieve revenue growth, greater efficiency, cost savings and regulatory compliance. In a digital-first world, nCino's single digital platform enhances the employee and client experience to enable financial institutions to more effectively onboard new clients, make loans and manage the entire loan life cycle, and open deposit and other accounts across lines of business and channels. Transforming how financial institutions operate through innovation, reputation and speed, nCino works with more than 1,200 financial institutions globally, whose assets range in size from $30 million to more than $2 trillion. For more information, visit: www.ncino.com.About Vancity Vancity is a values-based financial co-operative serving the needs of its more than 543,000 member-owners and their communities, with offices and 60 branches located in Metro Vancouver, the Fraser Valley, Victoria, Squamish and Alert Bay, within the unceded territories of the Coast Salish and Kwakwaka’wakw people. With $28.2 billion in assets plus assets under administration, Vancity is Canada’s largest community credit union. Vancity uses its assets to help improve the financial well-being of its members while at the same time helping to develop healthy communities that are socially, economically and environmentally sustainable.About Accenture Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services—all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 506,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com. MEDIA CONTACTS Claire Sandstrom, nCino Natalia Moose, nCino +1 646.520.0710 +1 910.248.4602 firstname.lastname@example.org email@example.com This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally include actions, events, results, strategies and expectations and are often identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. Any forward-looking statements contained in this press release are based upon nCino’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent nCino’s expectations as of the date of this press release. Subsequent events may cause these expectations to change and, except as may be required by law, nCino does not undertake any obligation to update or revise these forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect nCino’s business and financial results are included in reports filed by nCino with the U.S. Securities and Exchange Commission (available on our web site at www.ncino.com or the SEC's web site at www.sec.gov). Further information on potential risks that could affect actual results will be included in other filings nCino makes with the SEC from time to time.
Data from Supplemental Analyses to be Shared at Clinical Trials Think Tank MeetingSOUTH SAN FRANCISCO, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced additional results from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, will be presented at the 17th Global Cardiovascular Clinical Trialists Forum (CVCT) by John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, COSMIC-HF and GALACTIC-HF. CVCT is a global invitation-only meeting of opinion leaders across clinical research, industry and regulatory authorities. Session Title: Targeting the Vessels and the Heart: Oral Soluble Guanylate Cyclase Stimulator (Vericiguat) and Cardiac Myosin Activation (Omecamtiv Mecarbil) Presentation Title: GALACTIC-HF Main Results Presenter: John Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, San Francisco Veterans Affairs Medical Center and Executive Committee Chair, COSMIC-HF and GALACTIC-HF Date: Sunday, December 6, 2020 Time: 3:30 PM Central European TimeAbout CytokineticsCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next- generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics is also developing reldesemtiv, a fast skeletal muscle troponin activator for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of reldesemtiv to Phase 3 pending ongoing regulatory interactions. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the GALACTIC-HF clinical trial; statements relating to the METEORIC-HF clinical trial; Cytokinetics’ activities to advance the development of omecamtiv mecarbil; the potential benefits of omecamtiv mecarbil, including its ability to represent a novel therapeutic strategy to increase cardiac muscle function and restore cardiac performance; the potential approval of omecamtiv mecarbil by the FDA or any other regulatory authority; Amgen’s fulfillment of its undertakings regarding transition of the omecamtiv mecarbil and AMG 594 programs to Cytokinetics; any decision on the part of Servier to maintain or terminate its sublicense in respect of omecamtiv mecarbil prior to the effectiveness of the termination of the Amgen-Cytokinetics collaboration; Cytokinetics' and its partners' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; the nature of Amgen's decisions and activities with respect to the transfer of rights to develop and commercialize omecamtiv mecarbil and AMG 594 to Cytokinetics; standards of care may change, rendering Cytokinetics' drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics' collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Communications, Investor Relations (415) 290-3060
Unique COVID-19 testing model verified with strong demand from initial 20 sites: 7-Day average of 73 tests/day per site and $95 per test. Investor webinar scheduled December 10th (1 pm ET). Collection Site Rendering Figure 1 – New Collection Site with WillScot TrailerTORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- QuestCap Inc. (“QuestCap”) (NEO:QSC; OTC:COPRF; FRA:34C1) is pleased to announce strong initial test sales at its wholly owned subsidiary, Collection Sites, LLC. Highlights Include: * Surging test sales amid recent Collection Sites media coverage and increasing COVID-19 cases across the United States. Demand for Collection Sites unique value-proposition of convenient and effective COVID-19 testing verifies operational model; * Initial 20 sites showing strong tests sales with 7-day rolling average of 73 tests per day per site and average test price exceeding $95 per test; * Rapid antigen tests’ point-of-care capabilities allows for increased testing capacity, with one Collection Site recording sales of 186 tests in a single day; * The launch of 25 additional collection sites in hand-picked, high traffic locations across the United States, with installation beginning this week; * The leasing of new portable trailers from WillScot, drastically reducing upfront capital requirements and providing refuge for customers in the coming winter season; * Continued engagement with retailers, with up to 743 contracted collection sites across the United States with partners like Simon’s Property Group, Brookfield Properties, Sandor, among others; * QuestCap is hosting a Corporate Update webinar on Thursday, December 10th at 1 pm ET for investors (register here).“As COVID-19 cases continue to rise across the United States, Collection Sites testing centres are seeing increased demand from both consumers as well as businesses eager to offer COVID-19 testing to employees and customers,” says Mr. Doug Sommerville, CEO of QuestCap, Inc. “Having now refined our operational model with the launch of the first 20 cubes, we are now ready to expand our network and get convenient and effective COVID-19 test results to everyday Americans so we can flatten the curve.”Collection Sites Expands Test Offerings and Footprint Starting on November 16th, COVID-19 rapid antigen tests were distributed to the operating Collections Sites. These tests retail for US$99 per test, and are the most sought after by customers, with strong initial demand in the initial days. These tests also provide Collection Sites with the highest profit margin per test, strengthening profitability of each testing cube. The collection sites have an estimated capacity of up to 150 tests per day when fully staffed, where they operate 7 days a week. However, due to the point-of-Care capabilities of the rapid antigen tests, to date one Collection Site recorded sales of 186 tests in a single day, with multiple other sites exceeding 150 tests in a single day.As noted by Collection Sites President Tim Shelburn during the QuestCap investor webinar with The NEO Exchange (recording), the company continues to engage with retailers and similar businesses looking to host collection sites at their locations and will make further announcements as they are signed.To summarize, to date the following agreements have been signed, for a total of up to 743 contracted collection sites: * Brixmor – 340 Retail Locations * Brookfield Properties – 73 Shopping Mall Locations * H&S Energy, LLC – Up to 100 Gas and Convenience Locations * Sandor - 65 Big Boxstore Locations * Simons Property Group - 165 Shopping Mall Locations“Our initial strategy has been that of a land grab, securing convenient, high-traffic locations that will perform exceptionally during the upcoming holiday season and beyond,” commented Tim Shelburn, Collection Site President. “With over 700 sites secured and counting, we believe we have the best footprint in the country for offering convenient and effective COVID-19 testing. With the operational model now proven, our team is laser-focused on the execution fo the rollout of these sites.”25 New Collection Sites Launched With WillScot TrailersStarting this week, Collection Sites will rollout 25 portable trailers from WillScot in hand-picked high-traffic locations across the U.S., including states like Texas, Indiana, Pennsylvania, and Florida, among others. WillScot is a international company that sells or leases portable trailers to customers across the United States. After this initial site rollout with WillScot, Collection Sites will look to fulfill its previously announced network of collection sites.WillScot has a fleet in excess of 360,000 trailers globally and over 140,000 trailers across the United States. These trailers are spread out across the country and can be deployed to a desired site in 2-3 days. The use of WillScot trailers allows Collection Sites to drastically reduce the upfront capital requirements and delivery cost.These new trailers measure 20’ x 8’ and offer customers and staff reprieve from the outdoor conditions during the winter season, including built-in heating units.QuestCap Corporate Update WebinarQuestCap is hosting a Corporate Update webinar on Thursday December 10th at 1 pm ET that will provide investors with an update on the Company's business developments since the last update, with a primary focus on the Collection Sites subsidiary.Registration Link: https://us02web.zoom.us/webinar/register/WN_mvNt8yKqTyqCOCQ-7vyqMgAbout Collection Sites Collection Sites COVID-19 testing centers offer convenient access to rapid antibody and antigen tests - which take 8-10 minutes to administer and provide results in less than 24 hours. The sites also offer regular RT-PCR, with results within 24 hours of testing. The testing centres are powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. All tests can be administrered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.About QuestCap Inc. QuestCap Inc. (NEO:QSC; OTC:COPRF; FRA:34C1) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, QuestCap offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.QuestCap has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.QuestCap’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.For additional information, please contact:Doug Sommerville, CEO Doug.Sommerville@questcapinc.com +1 416-301-5418For investing inquiries please contact: Evan Veryard Evan.Veryard@questcapinc.comFor US media enquires please contact: Veronica Welch firstname.lastname@example.org +1-508-643-8000Cautionary Note Regarding Forward-looking InformationThis press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the results of the Collection Site testing cubes; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by QuestCap of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER THE NEO EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/27d1d1c7-6292-4580-ab59-789e14d5e9e7